Clinical translation of novel human pluripotent stem cell (hPSC)-based therapies for a wide range of diseases will require robust, scalable bioreactor technologies to manufacturing large quantities of therapeutic cells. While mouse PSC yields in bioreactors are comparable to traditional adherent culture (>50 fold expansion over 4 days), translation of hPSCs to suspension yields only 3–6 fold expansion over 7 days. We hypothesize that this discrepancy results from a cell state difference: mouse PSCs exist in an earlier developmental “naïve” state which has enhanced bioprocessing properties relative to the later “primed” state in which hPSCs exist.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Cytotherapy
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect